Drug Profile


Alternative Names: (S)-acetorphan; Bay-y-7432; BP-1.02; S-049; Sinorphan

Latest Information Update: 03 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioprojet
  • Developer Bayer; Bioprojet; Shionogi
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfur amino acids
  • Mechanism of Action Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 09 Jan 2003 A preclinical study has been added to the Heart Failure pharmacodynamics section
  • 09 Oct 2001 No-Development-Reported for Hypertension in France (PO)
  • 09 Oct 2001 No-Development-Reported for Hypertension in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top